<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665832</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1351002</org_study_id>
    <nct_id>NCT02665832</nct_id>
  </id_info>
  <brief_title>Study of DWJ1351 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetic characteristics of
      combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0 - 144 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 - 144 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1351</intervention_name>
    <arm_group_label>AB</arm_group_label>
    <arm_group_label>BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)</intervention_name>
    <arm_group_label>AB</arm_group_label>
    <arm_group_label>BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects aged 19 to 50 years

          -  Subjects whose body weight ≥ 55 kg and Body Mass Index(BMI) ≥ 18.0 kg/m2 and ≤ 27.0
             kg/m2

          -  Subject who was judged to be healthy and suitable for the participation by the
             investigator based on screening test results

          -  Subject who provided written informed consent to participate in this study

        Exclusion Criteria:

          -  Subject who had a severe allergy or allergic reactions to the amlodipine, olmesartan,
             rosuvastatin or related drugs

          -  Subject with sign or symptoms or previously diagnosed disease of liver, kidney,
             neurology, respiratory, endocrinology, hematology, cardiovascular, digestive system,
             reproductive system, neurology, psychology, ophthalmic and skin disease

          -  Subjects who had a serious clinical illness that can impact fate of drugs absorption

          -  Subject who shows vital signs with the number of systolic blood pressure of ≥150 mmHg
             or ≤100 mmHg, and the number of diastolic blood pressure of ≥100mmHg or ≤66mmHg

          -  Subject who have experienced drug abuse

          -  Subject who donates his blood (whole blood donation within last 2 months or plasma
             donation within last 1 month)

          -  Subject who has taken other clinical or licensed medication from another clinical
             trial within an 3-month period prior to the first administration of the study
             medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang-Joon Kim</last_name>
    <phone>+82 550 8708</phone>
    <email>sjkim050@daewoong.co.kr</email>
  </overall_contact>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

